Thyrotropin (TSH) stimulates survival and growth of thyroid cells via a seven transmembrane G proteincoupled receptor. TSH elevates the intracellular cyclic AMP (cAMP) levels activating protein kinase A (PKA). Recent evidence indicates that p21 Ras is required for TSH-induced mitogenesis, but the molecular mechanism(s) is not known. Here we report that Ras p21 activity is necessary for the Go-G1 transition in TSH induced cycle and that the downstream eector of Ras upon TSH signaling is p85-p110 PI3K. We show that PI3K inhibitors block TSH-induced DNA synthesis, cAMP-PKA stimulate the formation of the complex PI3K-p21 Ras and reduce the complex Ras-Raf1 in thyroid and other cells types. Moreover, PKA phosphorylates immunoprecipitated p85 and PKA phosphorylation of cell extracts signi®cantly stimulates the formation of the complex PI3K-Ras. We suggest that PKA phosphorylates p85 and stabilizes the complex p110-p85, enhancing the interaction PI3K and p21 Ras. Simultaneously, cAMP inhibits Raf-1-ERK signaling by decreasing Raf1 availability to Ras. Under these circumstances PI3K signaling is favored. These results indicate that PI3K is an important mediator of Ras eects in cAMP-induced proliferation and illustrates how cAMP can selectively in¯uence Ras eector pathways. Oncogene (2001) 20, 1186 ± 1192.
Introduction
Thyrotropin stimulates the survival, the growth and the dierentiation of thyroid cells via a seven-loop transmembrane receptor by activating a Gs protein, which induces adenylyl cyclase (Vassart and Dumont, 1992; Meinkoth et al., 1992) . cAMP mediates most, if not all, TSH biological eects (Harootuinian et al., 1993; Montminy, 1997) . cAMP binds the regulatory subunits of cAMP-dependent protein kinase (PKA) which releases free catalytic subunit Thompson et al., 1995; Burgering and Bos, 1995) . Although cAMP binds other proteins such as GDP-exchange factors (GEF) (Kawasaki et al., 1998; de Rooij et al., 1998 ), PKA appears to be necessary for the stimulation of growth and dierentiation by TSH in thyroid cells (Kupperman et al., 1993) .
Recent evidence indicates that Ras p21 is required for TSH induced mitogenesis, but Raf-1-ERK-1 pathway is not involved (Meinkoth et al., 1991; Al-Alawi et al., 1995) . Since Ras stimulates multiple eector pathways (Wu et al., 1993; Weissenger et al., 1997) , it is likely that other signals are activated in TSH treated cells. By using selective Ras mutants, which dier in the ability to bind Raf-1, it has been shown that Ral-GDS binding to Ras increases the growth rate of thyroid cells in the presence of TSH (Miller et al., 1997) . However, no consistent eect on cell proliferation was detected by stable expression of RalGDS or by the Ras mutant that selectively binds RalGDS (Miller et al., 1997 (Miller et al., , 1998 . Also, the role of non-PKA cAMP-binding proteins on cAMP-induced proliferation is questionable, since their eects on MAPK or DNA synthesis are Ras-independent (Kawasaki et al., 1998; de Rooij et al., 1998) .
Therefore, we set out to determine which Ras eector(s) are necessary for TSH-induced DNA synthesis by analysing: (1) when during TSH-cAMP induced cell cycle progression Ras activity was required; and (2) by measuring the complexes formed by Ras with Raf-1 and PI3K following TSH or cAMP stimuli.
We found that: (1) Ras activity is required in the early-mid G1 phase of the cycle of the thyroid cells, later it becomes dispensable; (2) TSH, cAMP or PKA signi®cantly stimulate the formation of the complex PI3K-Ras in 15 ± 30 min both in thyroid and other cell types. Conversely, under the same conditions the complex Ras-Raf-1 is inhibited.
Results
Ras and PI3K are necessary in early and mid G1 of the TSH-induced cycle in thyroid
To determine the precise temporal role of Ras activity in the cycle progression of thyroid cells, we constructed a rat thyroid cell line (FRTL-5) expressing the dominant negative form of Ha-Ras (N17) under the transcriptional control of the MMTV promoter. This TSH-dependent cell line expresses N17 (ca. 10-fold above the basal) when treated with dexamethasone (see the legend to Figure 1 ). The kinetics of Ras inactivation is the following: mRNA accumulation was observed 6 h after treatment; the protein levels increased 12 h after dexamethasone addition, and remained constant for up to 60 h (data not shown). Note that, to date, the biological eects of Ras inactivation in dierent cell types have been analysed by stable transfection assay or microinjection in single cells of selective inhibitors. The assay we used allows a rapid and ecient inactivation of Ras in a time dependent manner permitting the analysis of p21 function at particular points of the cell cycle (Hagiwara et al., 1993) . Thyroid cells (FRTL-5) enter S Phase 48 h after TSH stimulation (Feliciello et al., 2000) . TSH-induced DNA synthesis was inhibited in cells transfected with Ha-Ras N17 gene upon 2 mM dexamethasone treatment ( Figure  1a ). Dexamethasone treatment had no eect on control cells (Figure 1a) . Pulsing the cells with dexamethasone, 12 h before and/or after the initial TSH stimulation completely suppressed the peak of DNA synthesis at 48 h (Figure 1b , gray arrows and circles). Addition of dexamethasone 24 ± 36 h, after initial TSH stimulation, did not inhibit DNA synthesis measured at 48 or 56 h (Figure 1b black arrow and squares), although Ha-Ras N17 was eciently transcribed and translated (data not shown). Ras-inhibited cells did not enter G1 as indicated by low levels of immediate early genes Figure 1 Ras and PI3K activity are necessary for cell cycle progression of thyroid cells. (a) A FRTL-5 clone expressing the dominant negative Ha-Ras variant (N17) under the control of dexamethasone-inducible promoter (MMTV) was isolated and characterized as described in Materials and methods. This clone was serum and TSH starved for 2 days and treated with 2 mM dexamethasone (DEX) for 12 h in the presence of 0.5% serum. TSH was added after 12 h and DNA synthesis was measured 48 h later by thymidine incorporation (Feliciello et al., 2000) (striped bars). Open bars indicate the DNA synthesis in cells expressing RSV-NEO (see Materials and methods). (7) represents cells that did not receive any treatment. The data are the mean of three independent experiments. The DNA synthesis is shown as relative to TSH-induced DNA synthesis set to 1. Three other independent FRTL5 clones, expressing MMTV-N17 were tested under the same conditions with identical results. The presence of insulin with TSH signi®cantly increased the fraction of cycling cells (Feliciello et al., 2000) , but did not change the time course of the DNA synthesis block induced by dexamethasone. (b) FRTL-5-MMTV cells were treated with dexamethasone for 12 h at the time points indicated by the arrowheads (0, 12, 24) . TSH was added at time 0 and the DNA synthesis was measured 48 h after initial TSH stimulation). Closed squares represent the DNA synthesis in control cells (treated only with TSH, without dexamethasone). The gray arrows correspond to the DNA synthesis pro®le shown by the gray circles (dexamethasone added at time 0, 12 relative to TSH treatment); while the black arrow corresponds to the DNA synthesis pro®le shown by the black squares (dexamethasone added 24 h later TSH initial addition). The DNA synthesis of the samples treated with dexamethasone at 24 h was also determined at 72 and 84 h and it is shown as fold induction over the basal. (c) FRTL-5 cells were synchronized by starvation and induced with 10 mU/ml TSH and 1 mg/ml of insulin in F-12 medium containing 0.5% BSA. LY-294002 (50 mM) was added at time 0 and DNA synthesis was measured at 36 and 48 h (striped bars). Open bars correspond to cells that received no inhibitor. Under these conditions, the inhibitor treatment did not change the number of viable cells relative to untreated samples Oncogene cAMP stimulates Ras/PI3K I Ciullo et al (data not shown). TSH-induced DNA synthesis in FRTL-5 cells is also PI3K dependent since treatment of cells with LY-294002, a potent and selective PI3K inhibitor abrogated DNA synthesis before and after stimulation with the hormone (Figure 1c ). These eects were replicated by wortmannin, another speci®c inhibitor of PI3K (data not shown).
These data indicate that both Ras and PI3K are required for TSH-induced cell cycle progression and suggest that the two molecules are components of the same signaling cascade.
TSH, cAMP, PKA stimulate the formation of the complex Ras-PI3K
To explore the mechanism of TSH-induced mitogenesis, we analysed the complex formed between Ras and PI3K after TSH stimulation. To this end, we (Porcellini et al., 1995 (Porcellini et al., , 1997 . Total proteins were extracted, normalized for the transfection eciency (see Materials and methods), immunoprecipitated with antibodies against Ras and immunoblotted with antibodies against p85. cAMP levels were determined as described in Porcellini et al. (1997) . The cAMP levels in cells transfected with control DNA were set to 1. The ®gure shows the amount of p85 co-immunoprecipitated with Ras. The bottom panel is a Western blot with the anti-p21 Ras rabbit antibody. (c) Left panel: cAMP stimulates the formation of the complex Ras-PI3K (p110). The same as in a but the cells were stimulated 30 min (30') with 20 mM of a cAMP cell permeable analogous (CPT-cAMP, Sigma). The lane on the left indicates the immunoprecipitation of the same extracts with non speci®c antibodies (ctrl Ab). The Western blot was performed with anti p110 antibodies. The bottom panel is a Western blot with the anti-p21 Ras rabbit antibody. Right panel: TSH stabilizes the complex p85-p110a. FRTL-5 cells were treated 30 min with increasing concentrations of TSH (10 and 100 mU/ml), proteins extracted and immunoprecipitated for p110a. The Western blot was performed with anti-p85 antibodies. The bottom panel represents the immunoblot with anti p110 antibodies. (d) PKA stimulates the formation of the complex Ras-PI3K. NIH3T3 ®broblasts were transfected with expression vectors carrying the constitutively active TSH receptor indicated in (a), Ha-Ras-val12, tagged with the epitope AU5 (Ras), the PKA catalytic subunit (PKA) and LacZ gene under the control of RSV LTR (see Materials and methods). The extracts, normalized for the transfection eciency, were immunoprecipitated with the antibodies to AU5 and blotted with anti p85 antibodies, as in a. The complex Ras-PI3K is signi®cantly stimulated by the TSHR* and PKA. The bottom panel is a Western blot with the anti-p21 Ras rabbit antibody ctrl Ab indicate the immunoprecipitation of the transfected extracts with a non-speci®c mouse serum cAMP stimulates Ras/PI3K I Ciullo et al immunoprecipitated Ras from lysates of wild-type FRTL5 cells treated with TSH. The immunoprecipitates were resolved on a SDS ± PAGE, transferred to nitrocellulose and blotted with antibodies against p85, the regulatory subunit of PI3K. Figure 2a shows that increasing concentrations of TSH stimulated the amount of p85 in the p21 immunocomplex, suggesting that TSH enhances the binding of PI3K to Ras. When Ras was inhibited with N-17, as described above, TSH stimulation did not increase the Ras-PI3K complex (data not shown).
We have estimated in several independent experiments that the amount of p85 immunoprecipitated by p21 Ras was stimulated by 5 ± 7-fold by TSH treatment.
To prove that TSH receptor signaling was directly involved in the stimulation of Ras-PI3K complex formation, we transfected the wild type or a constitutively activated version of the receptor into NIH3T3 cells (which do not express the receptor). Expression of TSH receptor induces cAMP levels after TSH treatment, while the mutated form of the receptor constitutively increases cAMP levels, in the absence of TSH (Figure 2b and Porcellini et al., 1995 Porcellini et al., , 1997 . Treatment with TSH of transfected cells expressing wild type TSH receptor or the constitutive active receptor, induces the accumulation of the p85 subunit in Ras immunoprecipitates. Note that the amount of p85 in the Ras immunocomplex increases accordingly to the cAMP levels.
PI3K is formed by two subunits p85 (regulatory) and p110 (catalytic) (Fry 1994; Carpenter and Cantley, 1996) . Since p110 binds directly to Ras (Kodaki et al., 1994; Rodriguez-Viciana et al., 1994; Cheathaman et al., 1997) , we have analysed the complex p110-Ras in cells exposed 30 min to cAMP. Figure 2c (left panel) shows that similarly to p85, the binding of 110 to p21 Ras was stimulated by cAMP. We have also investigated whether the complex formed by p110 and p85 was stabilized upon TSH stimulation. To this end total extracts from FRTL-5 cells stimulated with increasing concentrations of TSH were immunoprecipitated with antibodies against p110 a, separated on a SDS gels and blotted with antibodies against p85. Figure 2c (right panel) shows that TSH stimulates the complex between p85 and p110 type a.
To show that PKA mediates the eects observed upon TSH stimulation on the Ras-PI3K complex, we transfected NIH3T3 ®broblasts with tagged active Ras (val12-HaRas-AU5), constitutively active TSH receptor or the catalytic subunit of PKA (Porcellini et al., 1995; Bonapace et al., 1990; Paolillo et al., 1999) . The extracts were immunoprecipitated with antibodies directed to the AU5 tag present in the Ras protein and blotted with antibodies against the p85 subunit of PI3K. Figure 2d shows that the complex, Ras and PI3K, was signi®cantly stimulated by the active TSH receptor and by PKA. Overexpression of active Ras did not increase the formation of the complex with PI3K (Figure 2d, lanes 2 and 4) . Only PKA (lane 3) or Figure 3 Interaction between p21 Ras, p70 Raf 1 and p85 PI3K. (a) MCF7 cells were treated for 30 min with cAMP with or without H89. H89 (4 mM) was added 2 h before of cAMP. Cells lysates were immunoprecipitated with control (the ®rst three lanes on the left) or anti-pan-Ras antibodies (the last three lanes on the right). Immunoprecipitates were resolved on 11.5% SDS ± PAGE blotted onto nitrocellulose ®lters and probed with anti-Ras, anti p70 Raf and anti p85 antibodies. (b) MCF7 cells were left untreated or were treated for 30 min with cAMP with or without H89 or with H89 alone. Cells lysates were immunoprecipitated with control or p85 P13-K antibodies and immunoprecipitates was blotted with anti-ras, anti p70 Raf and anti p85 antibodies. (c and d) The Raf/ Ras end PI-3K/Ras ratio was calculated as a ratio between integrated intensity, analysed by a NIH 1.61 software, of protein bands corresponding to p70 Raf and p21Ras, or to p85 PI-3K and p21Ras, respectively, in the immunoprecipitates with anti-ras antibodies, averaged from three dierent experiments active TSH receptor (lane 5) signi®cantly stimulated the complex p21-PI3K.
To test if cAMP stimulates the Ras-PI3K complex in other cell types, we have analysed the Ras-PI3K complex in another hormone dependent cell line MCF7, derived from a breast carcinoma. The cells were treated with the cAMP cell permeable analog (8Cl-cAMP) 40 min; cell lysates were immunoprecipitated with anti-Ras antibody and immunoblotted with anti-Raf1 and anti PI3K antibodies. Figure 3a shows that the complex between PI3K and Ras is stimulated by cAMP. Treatment of the cells with H89, a speci®c PKA inhibitor, abolished the formation of the complex. The complementary experiment was also performed on the same extracts (Figure 3b ): cell lysates were immunoprecipitated by anti p85 PI3K antibodies and immunoblotted with anti-Ras antibodies to detect Ras associated with PI3K. Thus, the data shown in Figure 3 indicate that, also in MCF7 cells, cAMP stimulates the association Ras and PI3K and this complex is dependent on PKA activity, because it is suppressed by the PKA inhibitor, H89. Figure 3d shows the increase of PI3K co-immunoprecipitated with Ras, expressed as PI3K/Ras ratio.
cAMP inhibits the formation of the complex Ras-Raf
Since Ras-GTP also binds Raf-1 (Moodie et al., 1993; Zhang et al., 1993) it was important to assess the eect of cAMP on Ras-Raf-1 complex. The experiments described in the Figure 3 , already address this issue. In fact, Figure 3a shows the association between Ras and Raf1 under basal conditions and after cAMP treatment. Raf content in the Ras immunoprecipitate was signi®cantly reduced upon cAMP stimulation. The Ras-Raf1 association was partially restored (approximately 40%) when cAMP was added in the presence of the PKA inhibitor (H89), suggesting that cAMP inhibition of Ras-Raf-1 complex was partly PKA dependent. Also, H89 had no eect on the basal levels of Ras-Raf1 complex. Figure 3c shows the Ras/Raf1 ratio values derived from three independent experiments.
Taken together these data indicate that cAMP stimulates the formation of the complex Ras-PI3K and simultaneously decreases the complex Ras-Raf1.
Phosphorylation of p85 by PKA
To determine the mechanism underlying the cAMP-PKA stimulatory eects on PI3K-Ras complex, p85 immunoprecipitated was from MCF7 cells and incubated in vitro with puri®ed PKA in the presence of [g
32
-P]ATP. Figure 4a shows that p85 is eciently and speci®cally phosphorylated by PKA almost exclusively in the presence of cAMP. Under the same conditions, p110 phosphorylation by PKA was undetectable and the cyclic nucleotide was without eect when the kinase was not added to immunoprecipitates (data not shown).
The link between the p85 phosphorylation by PKA and the formation of PI3K-Ras complex was investigated by the experiment shown in Figure 4b . Here, PKA and ATP were added to untreated extracts from MCF-7 cells in the presence of cAMP. p85 was then immunoprecipitated from the extracts and associated p21 ras was revealed by Western blot with anti Ras antibodies. The ®gure shows that PKA treatment of the extracts strongly stimulated the formation of a PI3K-Ras complex. Addition with H89 to the extracts completely abolished the PKA eect on p21-PI3K association, whereas this inhibitor alone did not aect the complex under basal conditions.
Discussion
In this study we show that Ras activity is necessary at the early stages of the cell cycle progression in TSH induced mitogenesis, in particular during the transition from quiescence to G1. Our data con®rm and extend previous reports implicating Ras, AKT and PI3K in TSH-cAMP induced proliferation (Cass and Meinkoth, cAMP and 4 mM PKA inhibitor (H89), or with 10 75 M cAMP and 40 mg/ml Protein Kinase A (Sigma) in absence, or in presence of 4 mM of H89. All samples were added with 100 mM ATP and incubated for 15 min at 308C. The reaction was stopped by transferring samples to an ice-cold bath. Each sample was then divided in two aliquots and added with either non-immune or anti p85-PI3K and immunoprecipitated as described under Materials and methods. Immunoprecipitates were run on 11,5% SDS ± PAGE blotted onto nitrocellulose ®lters and probed with anti p85 and anti-ras antibodies cAMP stimulates Ras/PI3K I Ciullo et al 2000; De Vita et al., 2000; Cass et al., 1999) . We studied the involvement of both molecules in this signaling cascade one step further and show that these two proteins interact upon cAMP stimulation. This interaction can be seen between the endogenous gene products in thyroid cells upon TSH or cAMP stimulation. However it is not unique to thyroid cells since it can also be observed in MCF7 (Figures 3 and  4) . Conversely, under the same conditions the RasRaf1 complex is down regulated by cAMP ( Figure 3) . As to the molecular mechanism underlying these eects we present evidence indicating that p85 is a substrate of PKA and that PKA-phosphorylation of p85 stabilizes its binding to the p110 subunit. Stabilization of the complex p85-p110 might be the initial step leading to the preferential accumulation of Ras-PI3K upon cAMP stimulation. TSH stimulated the association of the two PI3K subunits (Figure 2c ) whereas under the same experimental conditions insulin, that does not activate the PKA pathway, was not able to modify the p85-p110 complex (data not shown). Also, the activity of PI3K was not stimulated by cAMP-PKA (data not shown). We suggest that the recruitment of the enzyme under the membrane appears to be the key factor necessary for cAMP-induced mitogenesis.
As to the mechanism responsible for the decreased amount of Raf bound to Ras, we ®nd that it is partly PKA-independent. Raf1 is phosphorylated by PKA in vitro and in vivo (Hafner et al., 1994; Wu et al., 1993) . PKA-phosphorylated Raf1 binds less eciently Ras (Hafner et al., 1994) . However, we presume that another target activated by cAMP binding but not by PKA contributes to Raf1 inactivation. We are exploring the possibility that a cAMP-GEF activates a GTP binding protein that binds avidly Raf1, thus reducing the eective concentration of available Raf1 to Ras. Therefore, it appears that cAMP reduces RasRaf1 complex by two mechanisms: (1) by reducing Raf1 anity to Ras via PKA (Hafner et al., 1994; Wu et al., 1993); and (2) by targeting Raf1 to another GTP binding protein in a PKA-independent fashion.
Taken together the data we present contain two general implications that can be extended to other cell types: (1) cAMP simultaneously activates two pathways, the ®rst by directly activating PKA and immediate early genes (Feliciello et al., 2000) , the other by in¯uencing the selection of Ras eectors (PI3K versus Raf-1). These dual eects can be detected not only in thyroid cells, but also in mammary cells ( Figures 3 and 4) ; (2) we have data indicating that cAMP does not activate directly Ras, but requires active Ras to stimulate the progression into cycle of thyroid cells. Prolonged serum starvation reduces cAMP induction of the Ras-PI3K complex (data not shown). Also, albeit the proliferation of thyroid cells is strictly dependent on TSH and cAMP, TSH-stimulated cells progress very ineciently into cycle in the absence of insulin or serum (Feliciello et al., 2000; Tramontano et al., 1988) . Serum or insulin potently synergize TSHinduced mitogenesis, indicating that insulin renders the cell permissive to TSH-cAMP by activating Ras.
The data we have presented provide a molecular framework that explain insulin and TSH eects on the growth of thyroid cells and illustrate how cAMP can selectively in¯uence Ras eector pathways in many cell types.
Materials and methods

Cell lines, DNA plasmids, and transfections
The FRTL5 cell line is a thyroid cell line, which has been extensively characterized with respect to thyroglobulin expression and TSH-dependent growth (Feliciello et al., 2000; Ambesi-Impiombata et al., 1980) . MCF-7 human breast carcinoma cells were routinely grown as previously described (Migliaccio et al., 1996) . Cells were maintained for 24 h before the experiments in DMEM without phenol-red and supplemented with 0.5% charcoal-stripped FCS FRTL5 clone expressing the transdominant negative Ras was generated by co-transfecting FRTL5 cells with the HaRas N-17 mutant (Indol® et al., 1995) under the control of the long terminal repeats of mammary tumor virus (MMTV) and the aminoglycoside phosphotransferase gene driven by the long terminal repeats of Rous sarcoma virus (RSV-NEO) (Bonapace et al., 1990) . Neomycin resistant clones were isolated and characterized for NEO and Ha-N17 copy number, expression by Northern and Western blots in the presence or absence of dierent concentrations of dexamethasone (0.1 ± 10 mM for 12 h). Since FRTL5 express mostly the Ki Ras isoform, Ha 17 expression was monitored with speci®c antibodies to Ha-Ras (Santa Cruz, CA, USA)
DNA synthesis
DNA synthesis in FRTL5 cells was monitored by [ 3 H]-thymidine incorporation as previously described (Feliciello et al., 2000) . Cells were rendered quiescent by starvation for 72 h. In basal medium (Coons modi®ed F12 supplemented with 0.3% BSA). Experiments were performed in triplicate and the data represent a mean of four independent experiments, all which gave similar results. Cell cycle progression (G0, G1, and S phases) was monitored bȳ uorescence-activated cell sorter analysis. Quiescent (G0) FRTL5 cells did not express early genes (cmyc and c-fos). These genes were induced by TSH (Miller et al., 1997; Rodriguez-Viciana et al., 1994) . Cyclin D and cyclin A were induced 24 h after continuous treatment with TSH. PCNA analysed by immuno¯uorescence appeared 36 h following continuous TSH treatment.
Antibodies and immunoblot analyses
Antibodies to the endogenous and untagged proteins were the following: Ras (pan-Ras, Santa Cruz, CA, USA), and for the PI3K subunits p85, p110 a (goat polyclonal, Santa Cruz, CA, USA). The antibody against the AU5 tag was purchased from Babco (USA). Western blot analyses were carried out as previously described (Feliciello et al., 2000) .
Brie¯y, the lysis buer was: Tris-HCl pH 7.4, 50 mM, NaCl 100 mM, EDTA, 2 mM NaMoO 4 20 mM, 50 mM NaF, 0.1 mM Na 3 VO 4 Nonidet NP-40 1% and a protease inhibitor cocktail.
Cell lysates (2 mg/ml) were incubated with 5 mg of p21 ras and p85 PI3K antibodies overnight at 48C. At the end of incubation, 40 ml of a 50% of a suspension of protein A/GOncogene cAMP stimulates Ras/PI3K I Ciullo et al sepharose were added and incubation continued for an additional 30 min. The samples were centrifuged and pellets washed with 1 ml of lysis buer for three times, eluted by Laemmli Page SDS sample buer. Proteins were run on electrophoresis and transferred onto nitrocellulose ®lters.
The ®lters were soaked in TTBS 0.05% Tween containing 5% NFM for 1 h At the end of this incubation, they were incubated overnight with indicated antibodies (1 mg/ ml in BSA 3% TTBS). After washing, the ®lters with peroxidase linked antibodies diluted 1/3000 in TTBS 3% NFM for 45 min. Finally, the ®lters were washed again and revealed by ECL according to the manufacturer instruction.
